Differential effects of ontamalimab versus vedolizumab on immune cell trafficking in intestinal inflammation and IBD.
Lisa Lou SchulzeEmily BeckerMark DeddenLi-Juan LiuChiara van PassenMariam Mohamed AbdouTanja M MüllerMaximilian WiendlKaren A-M UllrichImke AtreyaMoritz LeppkesArif B EkiciPhilipp KirchnerMichael StürzlDan SextonDeborah PalliserRaja AtreyaBritta Siegmundnull nullMarkus F NeurathSebastian ZundlerPublished in: Journal of Crohn's & colitis (2023)
Ontamalimab has unique and broader mechanisms of action compared to vedolizumab. However, this seems to be compensated by redundant cell trafficking circuits and leads to similar preclinical efficacy of anti-α4β7 and anti-MAdCAM-1 treatment. These results will be important for the interpretation of pending phase III data.
Keyphrases
- phase iii
- ulcerative colitis
- open label
- cell therapy
- clinical trial
- patients with inflammatory bowel disease
- oxidative stress
- single cell
- placebo controlled
- phase ii
- double blind
- big data
- electronic health record
- randomized controlled trial
- replacement therapy
- mesenchymal stem cells
- stem cells
- artificial intelligence
- bone marrow
- machine learning